Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • Wade Davis
    Junior Member
    • Mar 2009
    • 2

    #1

    454 for RNA-Seq for 2 group comparison

    I've been reading papers on RNA-Seq and it seems Illumina is the dominant technology at this point, mostly because the large number of reads. I am interested in 454 and want to know about coverage necessary for RNA-seq.

    Some papers have shown that for mammalian genomes, the number of unique start sites reaches a plateau after about 80 million (non-unique) mapped reads for Illumina 35 bp length reads. Someone else has shown that 80% of yeast genes were detected after 4 million uniquely mapped reads (once again Illumina).

    Obviously, you don't get near that many reads on 454 reads per run, but the reads are much longer. What are people's thoughts on the number of reads needed from 454 (say Titanium) to get acceptable coverage for RNA-seq for the human transcriptome. Any opinions out there?

    Keep in mind, the goal here is not to necessary hit rare transcripts, but find differences in most common transcripts, e.g. tryi to mimic what is done with microarray 2 group comparison...

    Thanks,
    Wade
    Last edited by Wade Davis; 03-26-2009, 11:54 AM.

Latest Articles

Collapse

  • SEQadmin2
    16S/ITS Profiling vs. Shotgun Metagenomics: What Changes in Your Workflow?
    by SEQadmin2




    NGS has revolutionized clinical microbiology by offering new ways to identify and surveil pathogens without prior knowledge of the target. One popular approach is 16S rRNA and ITS amplicon sequencing, which targets specific microbial markers. But studies are increasingly incorporating shotgun metagenomics, a technique that sequences all DNA from a sample without targeting specific microbial markers. This approach allows more detailed taxonomic classification, detection...
    Today, 06:46 AM
  • SEQadmin2
    Multiomic Liquid Biopsy: What DNA/RNA Panels Reveal That DNA Alone Can’t
    by SEQadmin2



    Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?

    Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating
    ...
    10-14-2026, 09:55 AM

ad_right_rmr

Collapse

News

Collapse

Topics Statistics Last Post
Started by SEQadmin2, 10-28-2026, 09:57 AM
0 responses
24 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 10-28-2026, 09:51 AM
0 responses
15 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 10-22-2026, 11:13 AM
0 responses
71 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 10-22-2026, 10:48 AM
0 responses
48 views
0 reactions
Last Post SEQadmin2  
Working...